Next Article in Journal
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine
Next Article in Special Issue
Progress and Prospects of Anti-HBV Gene Therapy Development
Previous Article in Journal
Development of Ophiocordyceps sinensis through Plant-Mediated Interkingdom Host Colonization
Previous Article in Special Issue
Human Leukocyte Antigen Class II Alleles Are Associated with Hepatitis C Virus Natural Susceptibility in the Chinese Population
Review

Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence

1
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
2
Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Tatsuo Kanda
Int. J. Mol. Sci. 2015, 16(8), 17494-17513; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms160817494
Received: 24 May 2015 / Revised: 25 July 2015 / Accepted: 27 July 2015 / Published: 30 July 2015
(This article belongs to the Special Issue Viral Hepatitis Research)
Hepatitis B often progresses to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). Although newer nucleos(t)ide analogues result in >90% viral and hepatitis activity control, severely decompensated patients still need OLT because of drug-resistant virus, acute exacerbation, or hepatocellular carcinoma. Acute hepatitis B is also an indication for OLT, because it can progress to fatal acute liver failure. After OLT, the hepatitis B recurrence rate is >80% without prevention, while >90% of transplant recipients are clinically controlled with combined hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogue treatment. However, long-term HBIG administration is associated with several unresolved issues, including limited availability and extremely high cost; therefore, several treatment protocols with low-dose HBIG, combined with nucleos(t)ide analogues, have been investigated. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using an HBV envelope (HBs) antigen vaccine. Patients who are not HBV carriers, such as those with acutely infected liver failure, are good candidates for vaccination. For chronic HBV carrier liver cirrhosis patients, a successful vaccine response can only be achieved in selected patients, such as those treated with experimentally reduced immunosuppression protocols. The present protocol for post-OLT HBV control and the future prospects of newer treatment strategies are reviewed. View Full-Text
Keywords: acute hepatitis B; liver cirrhosis; hepatitis B virus vaccine; liver transplantation; hepatitis B immunoglobulin; nucleos(t)ide analogue acute hepatitis B; liver cirrhosis; hepatitis B virus vaccine; liver transplantation; hepatitis B immunoglobulin; nucleos(t)ide analogue
Show Figures

Graphical abstract

MDPI and ACS Style

Takaki, A.; Yasunaka, T.; Yagi, T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int. J. Mol. Sci. 2015, 16, 17494-17513. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms160817494

AMA Style

Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. International Journal of Molecular Sciences. 2015; 16(8):17494-17513. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms160817494

Chicago/Turabian Style

Takaki, Akinobu, Tetsuya Yasunaka, and Takahito Yagi. 2015. "Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence" International Journal of Molecular Sciences 16, no. 8: 17494-17513. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms160817494

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop